Clinical Trials
31 trialsMorningLyte
The Lymphoma Academic Research Organisation
FIL_GAZEBO
Fondazione Italiana Linfomi - ETS
Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma
University of Washington
ZGR in TN FL
Institute of Hematology & Blood Diseases Hospital, China
REFRACT
University of Birmingham
GAZAI
Heidelberg University
Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma
University of California, Davis
Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma
M.D. Anderson Cancer Center
Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma
Dana-Farber Cancer Institute
Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas
Thomas Jefferson University
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
Emory University
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma
The First Affiliated Hospital with Nanjing Medical University
O-ICE
New York Medical College
Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma
University of Washington
Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma
M.D. Anderson Cancer Center
Zanubrutinib Combined With G-CVP in Previously Untreated FL
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma
University of California, Davis
FLUORO
Olivia Newton-John Cancer Research Institute
GAUDEALIS
Fondazione Italiana Linfomi - ETS
Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)
Ruijin Hospital
Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma
The First Affiliated Hospital of Xiamen University
LEVERAGE
Peter MacCallum Cancer Centre, Australia
A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma
University of Chicago
Alternative-C
Ludwig-Maximilians - University of Munich
Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma
OHSU Knight Cancer Institute
A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL
Ruijin Hospital
Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas
The Lymphoma Academic Research Organisation
Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients
Swiss Cancer Institute
GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma
Johannes Gutenberg University Mainz
FLMRD
Meir Medical Center